Pipeline.

GH001

GH001 is our innovative drug product for 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) administration via a proprietary inhalation approach. 

 

A healthy volunteer study with GH001 has been completed, establishing the safety of the inhalation approach and the appropriate GH001 dose range for further clinical studies.

 

A Phase 1/2 study with GH001 in patients with Treatment-Resistant Depression is ongoing.

GH002

GH002, our innovative injectable formulation of 5-MeO-DMT, is expected to enter the clinic soon.